Rifapentine is an entry and replication inhibitor against yellow fever virus both in vitro and in vivo

References

• Yellow fever in Africa and the Americas, 2016. Wkly Epidemiol Rec. 2017;92(32):442–452.
   PubMedGoogle Scholar
• Jentes ES, Poumerol G, Gershman MD, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the informal WHO working group on geographic risk for yellow fever. Lancet Infect Dis. 2011;11(8):622–632.
   PubMed Web of Science ®Google Scholar
• Carrington CV, Auguste AJ. Evolutionary and ecological factors underlying the tempo and distribution of yellow fever virus activity. Infect Genet Evol. 2013;13:198–210.
   PubMed Web of Science ®Google Scholar
• Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol. 2015;64:160–173.
   PubMed Web of Science ®Google Scholar
• Douam F, Ploss A. Yellow fever virus: knowledge gaps impeding the fight against an old foe. Trends Microbiol. 2018;26(11):913–928.
   PubMed Web of Science ®Google Scholar
• de Oliveira Figueiredo P, Stoffella-Dutra AG, Barbosa Costa G, et al. Re-emergence of yellow fever in Brazil during 2016–2019: challenges, lessons learned, and perspectives. Viruses. 2020;12(11):1233.
   PubMed Web of Science ®Google Scholar
• Lataillade LG, Vazeille M, Obadia T, et al. Risk of yellow fever virus transmission in the Asia-Pacific region. Nat Commun. 2020;11(1):5801.
   PubMed Web of Science ®Google Scholar
• Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001;1(1):11–20.
   PubMedGoogle Scholar
• Higuera A, Ramirez JD. Molecular epidemiology of dengue, yellow fever, Zika and chikungunya arboviruses: an update. Acta Trop. 2019;190:99–111.
   PubMed Web of Science ®Google Scholar
• Best SM. The many faces of the flavivirus NS5 protein in antagonism of type I interferon signaling. J Virol. 2017;91(3):e01970–16.
   PubMed Web of Science ®Google Scholar
• Selisko B, Wang C, Harris E, et al. Regulation of flavivirus RNA synthesis and replication. Curr Opin Virol. 2014;9:74–83.
   PubMed Web of Science ®Google Scholar
• Julander JG, Morrey JD, Blatt LM, et al. Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model. Antiviral Res. 2007;73(2):140–146.
   PubMed Web of Science ®Google Scholar
• Julander JG, Shafer K, Smee DF, et al. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009;53(1):202–209.
   PubMed Web of Science ®Google Scholar
• Julander JG, Bantia S, Taubenheim BR, et al. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model. Antimicrob Agents Chemother. 2014;58(11):6607–6614.
   PubMed Web of Science ®Google Scholar
• Faria NR, Kraemer MUG, Hill SC, et al. Genomic and epidemiological monitoring of yellow fever virus transmission potential. Science. 2018;361(6405):894–899.
   PubMed Web of Science ®Google Scholar
• Alfarisi O, Alghamdi WA, Al-Shaer MH, et al. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? Expert Rev Clin Pharmacol. 2017;10(10):1027–1036.
   PubMed Web of Science ®Google Scholar
• Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 2001;104(6):901–912.
   PubMed Web of Science ®Google Scholar
• Rothstein DM. Rifamycins, alone and in combination. Cold Spring Harb Perspect Med. 2016;6(7):a027011.
   PubMed Web of Science ®Google Scholar
• Dorman SE, Goldberg S, Stout JE, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis. 2012;206(7):1030–1040.
   PubMed Web of Science ®Google Scholar
• Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis. 2006;43(11):1468–1475.
   PubMed Web of Science ®Google Scholar
• Guo F, Wu S, Julander J, et al. A novel benzodiazepine compound inhibits yellow fever virus infection by specifically targeting NS4B protein. J Virol. 2016;90(23):10774–10788.
   PubMed Web of Science ®Google Scholar
• Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol. 2002;76(24):13001–13014.
   PubMed Web of Science ®Google Scholar
• Guo F, Zhao X, Gill T, et al. An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses. Antiviral Res. 2014;107:56–65.
   PubMed Web of Science ®Google Scholar
• de Freitas CS, Higa LM, Sacramento CQ, et al. Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. PLoS Negl Trop Dis. 2019;13(1):e0007072.
   PubMed Web of Science ®Google Scholar
• Yi Z, Sperzel L, Nurnberger C, et al. Identification and characterization of the host protein DNAJC14 as a broadly active flavivirus replication modulator. PLoS Pathog. 2011;7(1):e1001255.
   PubMed Web of Science ®Google Scholar
• Patkar CG, Larsen M, Owston M, et al. Identification of inhibitors of yellow fever virus replication using a replicon-based high-throughput assay. Antimicrob Agents Chemother. 2009;53(10):4103–4114.
   PubMed Web of Science ®Google Scholar
• Dal Piaz F, Cotugno R, Lepore L, et al. Chemical proteomics reveals HSP70 1A as a target for the anticancer diterpene oridonin in Jurkat cells. J Proteomics. 2013;82:14–26.
   PubMed Web of Science ®Google Scholar
• Chen L, Lv D, Chen X, et al. Biosensor-based active ingredients recognition system for screening STAT3 ligands from medical herbs. Anal Chem. 2018;90(15):8936–8945.
   PubMed Web of Science ®Google Scholar
• He Z, Zhu X, Wen W, et al. Dengue virus subverts host Innate immunity by targeting adaptor protein MAVS. J Virol. 2016;90(16):7219–7230.
   PubMed Web of Science ®Google Scholar
• Kleinert RDV, Montoya-Diaz E, Khera T, et al. Yellow fever: integrating current knowledge with technological innovations to identify strategies for controlling a re-emerging virus. Viruses. 2019;11(10):960.
   PubMed Web of Science ®Google Scholar
• Yau C, Gan ES, Kwek SS, et al. Live vaccine infection burden elicits adaptive humoral and cellular immunity required to prevent Zika virus infection. EBioMedicine. 2020;61:103028.
   PubMed Web of Science ®Google Scholar
• Chen LH, Wilson ME. Yellow fever control: current epidemiology and vaccination strategies. Trop Dis Travel Med Vaccines. 2020;6:1.
   PubMedGoogle Scholar
• Garriga D, Headey S, Accurso C, et al. Structural basis for the inhibition of poxvirus assembly by the antibiotic rifampicin. Proc Natl Acad Sci U S A. 2018;115(33):8424–8429.
   PubMed Web of Science ®Google Scholar
• Green M, Bragdon J, Rankin A. 3-Cyclic amine derivatives of rifamycin: strong inhibitors of the DNA polymerase activity of RNA tumor viruses. Proc Natl Acad Sci U S A. 1972;69(5):1294–1298.
   PubMed Web of Science ®Google Scholar
• Szabo C, Bissell MJ, Calvin M. Inhibition of infectious Rous sarcoma virus production by rifamycin derivative. J Virol. 1976;18(2):445–453.
   PubMed Web of Science ®Google Scholar
• Perera-Lecoin M, Meertens L, Carnec X, et al. Flavivirus entry receptors: an update. Viruses. 2013;6(1):69–88.
   PubMed Web of Science ®Google Scholar
• Selisko B, Papageorgiou N, Ferron F, et al. Structural and functional basis of the fidelity of nucleotide selection by flavivirus RNA-dependent RNA polymerases. Viruses. 2018;10(2):59.
   PubMed Web of Science ®Google Scholar
• Dubankova A, Boura E. Structure of the yellow fever NS5 protein reveals conserved drug targets shared among flaviviruses. Antiviral Res. 2019;169:104536.
   PubMed Web of Science ®Google Scholar